Skip to main content

CLNN

Stock
Health Care
Biotechnology

Performance overview

CLNN Price
Price Chart

Forward-looking statistics

Beta
0.50
Risk
90.13%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

clene has a new vision for a pharmaceutical future using therapeutic elements in clean, new nanoforms. our patented clean-surface nanosuspension™ (csn) technology produces clean-surface nanocrystals at commercially viable rates. by coupling high-purity metallic donor materials with high-purity water, csn unlocks the potential of therapeutic nanoparticles and represents a clean break from the standard paradigm of small-molecule drugs and large-molecule biologics.

Company info

SectorHealth Care
IndustryBiotechnology
Employees73
Market cap$47.8M

Fundamentals

Enterprise value$46.2M
Revenue$350.0K
Revenue per employee
Profit margin79.53%
Debt to equity-4.21

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$4.03
Dividend per share
Revenue per share$0.05
Avg trading volume (30 day)$447K
Avg trading volume (10 day)$179K
Put-call ratio

Macro factor sensitivity

Growth-0.4
Credit+1.7
Liquidity-3.8
Inflation-1.9
Commodities+3.1
Interest Rates-0.3

Valuation

Dividend yield0.00%
PEG Ratio-1.10
Price to sales100.09
P/E Ratio-1.10
Enterprise Value to Revenue132.09
Price to book-6.92

Upcoming events

Next earnings dayMay 7, 2025
Next dividend day
Ex. dividend day

News

Clene Inc. (CLNN) Reports Q1 Loss, Lags Revenue Estimates

Clene Inc. (CLNN) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $1.10. This compares to loss of $1.80 per share a year ago.

Zacks Investment Research (May 7, 2025)
HC Wainwright Initiates Coverage On This Nanocrystals Stock

H.C. Wainwright initiated coverage on Clene Inc (NASDAQ: CLNN) with a Buy rating and a $16 price target.  Clene is focused on the development of novel clean-surfaced nanotechnologies consisting of transition element nanocrystals for central nervous disorders, such as.

Benzinga (July 18, 2022)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free